Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
rydapt | New Drug Application | 2025-06-18 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
myeloid leukemia acute | — | D015470 | C92.0 |
hematologic neoplasms | — | D019337 | — |
systemic mastocytosis | — | D034721 | C96.21 |
Expiration | Code | ||
---|---|---|---|
MIDOSTAURIN, RYDAPT, NOVARTIS | |||
2024-04-28 | ODE-140, ODE-141 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 9 | 11 | 3 | — | 4 | 22 |
Myeloid leukemia acute | D015470 | — | C92.0 | 9 | 10 | 3 | — | 4 | 22 |
Myeloid leukemia | D007951 | — | C92 | 7 | 10 | 3 | — | 4 | 20 |
Drug common name | Midostaurin |
INN | midostaurin |
Description | Midostaurin is an organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine. It has a role as an EC 2.7.11.13 (protein kinase C) inhibitor and an antineoplastic agent. It is an indolocarbazole, an organic heterooctacyclic compound, a member of benzamides and a gamma-lactam. It is functionally related to a staurosporine. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4 |
PDB | — |
CAS-ID | 120685-11-2 |
RxCUI | — |
ChEMBL ID | CHEMBL608533 |
ChEBI ID | 63452 |
PubChem CID | 9829523 |
DrugBank | DB06595 |
UNII ID | ID912S5VON (ChemIDplus, GSRS) |